Jane Street Group LLC Grows Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Jane Street Group LLC increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 26.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 385,594 shares of the company's stock after purchasing an additional 79,942 shares during the period. Jane Street Group LLC owned 0.26% of MiMedx Group worth $3,709,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of MDXG. IMG Wealth Management Inc. acquired a new stake in MiMedx Group during the 4th quarter worth approximately $28,000. Van ECK Associates Corp purchased a new position in MiMedx Group during the 4th quarter worth $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after acquiring an additional 2,837 shares in the last quarter. AlphaQuest LLC purchased a new stake in MiMedx Group during the fourth quarter worth about $88,000. Finally, Savant Capital LLC acquired a new position in MiMedx Group during the fourth quarter worth about $100,000. Institutional investors and hedge funds own 79.15% of the company's stock.

Insider Buying and Selling at MiMedx Group

In related news, CEO Joseph H. Capper purchased 200,000 shares of MiMedx Group stock in a transaction dated Friday, May 2nd. The shares were bought at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the purchase, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares in the company, valued at approximately $3,473,004.42. This represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last quarter. 1.70% of the stock is currently owned by insiders.

MiMedx Group Stock Down 0.6%

Shares of MiMedx Group stock traded down $0.04 during midday trading on Friday, reaching $7.05. 614,522 shares of the company's stock traded hands, compared to its average volume of 693,539. The company has a market cap of $1.04 billion, a price-to-earnings ratio of 12.82 and a beta of 1.85. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company's 50 day simple moving average is $7.19 and its 200 day simple moving average is $8.19.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. Equities analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MDXG has been the subject of several recent analyst reports. StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.